Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials ; volume:22 ; number:1 ; day:26 ; month:1 ; year:2022 ; pages:1-8 ; date:12.2022
BMC cancer ; 22, Heft 1 (26.1.2022), 1-8, 12.2022
- Creator
-
Grayling, Michael J.
McMenamin, Martina
Chandler, Robert
Heer, Rakesh
Wason, James M. S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09227-7
- URN
-
urn:nbn:de:101:1-2022050620222985573762
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Grayling, Michael J.
- McMenamin, Martina
- Chandler, Robert
- Heer, Rakesh
- Wason, James M. S.
- SpringerLink (Online service)
Other Objects (12)
Ureter metastatic castration-resistant prostate cancer: a case report
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Ureter metastatic castration-resistant prostate cancer: a case report
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
Ureter metastatic castration-resistant prostate cancer: a case report
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey